(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANTICORPOS ANTI-CD122 E SEUS USOS

Em AnáliseInvention PatentPCT · US2023075600

Application data

Invention Patent ANTICORPOS ANTI-CD122 E SEUS USOS de FORTE SUBSIDIARY, INC. — IPC A61K 39/395
Invention Patent ANTICORPOS ANTI-CD122 E SEUS USOS de FORTE SUBSIDIARY, INC. — IPC A61K 39/395. Drawing published by the INPI in the Industrial Property Gazette.

Number

112025006210

Type

Invention Patent

Filing

09/29/2023

Publication

09/30/2025

PCT

US2023075600

Progress at the INPI

Examination not yet requested
  1. Filing09/29/23
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

Examination has not been requested yet. Without that request by 09/29/2026, the application is definitively abandoned (art. 33 of the Brazilian IP Act).

Deadline to request examination:09/29/2026(35 days left)

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 09/30/2025. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

FORTE SUBSIDIARY, INC.

US

Inventors

P. W. (pessoa física)

US

Technical data

IPC Classification

Priority claims

US

63/377,847 · 09/30/2022

Abstract

ANTICORPOS ANTI-CD122 E SEUS USOS. A presente invenção apresenta, em certos aspectos, anticorpos anti-CD122 e composições farmacêuticas que compreendem anticorpos anti-CD122. Em algumas modalidades, os anticorpos anti-CD122 e as composições farmacêuticas compreendendo anticorpos anti-CD122 podem ser usados para ter como alvo tecidos e células que expressam CD122.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

09/30/2025

RPI 2856

Alteração de dados cadastrais

#1.1

04/08/2025

RPI 2831

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.